Yifan Xinfu Pharmaceutical Co Ltd (002019) — Cash Flow Reinvestment Rate
Yifan Xinfu Pharmaceutical Co Ltd (002019) has a Cash Flow Reinvestment Rate of 4.60x as of September 2025, reinvesting CN¥184.68 Million (capex CN¥184.68 Million ) from operating cash flow of CN¥40.18 Million. Explore Yifan Xinfu Pharmaceutical Co Ltd capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Yifan Xinfu Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2003–2025)
Historical reinvestment intensity for Yifan Xinfu Pharmaceutical Co Ltd across 21 annual periods. Also explore Yifan Xinfu Pharmaceutical Co Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Yifan Xinfu Pharmaceutical Co Ltd (2003–2025)
Year-by-year capital reinvestment analysis for Yifan Xinfu Pharmaceutical Co Ltd. For live market cap and broader valuation context, see market value of Yifan Xinfu Pharmaceutical Co Ltd.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.40x | CN¥639.96 Million | CN¥458.37 Million | CN¥559.23 Million | ▲ +26.7% |
| 2024 | 1.10x | CN¥705.83 Million | CN¥640.73 Million | CN¥628.16 Million | ▼ -63.0% |
| 2023 | 2.97x | CN¥1.04 Billion | CN¥348.58 Million | CN¥504.09 Million | ▲ +15.8% |
| 2022 | 2.57x | CN¥1.21 Billion | CN¥472.07 Million | CN¥542.27 Million | ▲ +21.2% |
| 2021 | 2.12x | CN¥638.34 Million | CN¥301.23 Million | CN¥571.74 Million | ▲ +216.7% |
| 2020 | 0.67x | CN¥741.71 Million | CN¥1.11 Billion | CN¥715.71 Million | ▼ -34.2% |
| 2019 | 1.02x | CN¥952.57 Million | CN¥937.24 Million | CN¥866.07 Million | ▼ -7.3% |
| 2018 | 1.10x | CN¥1.28 Billion | CN¥1.17 Billion | CN¥729.21 Million | ▲ +17.4% |
| 2017 | 0.93x | CN¥1.06 Billion | CN¥1.13 Billion | CN¥485.86 Million | ▼ -39.4% |
| 2016 | 1.54x | CN¥1.32 Billion | CN¥855.85 Million | CN¥287.50 Million | ▲ +131.9% |
| 2015 | 0.66x | CN¥267.15 Million | CN¥401.96 Million | CN¥217.15 Million | ▲ +3.8% |
| 2014 | 0.64x | CN¥89.51 Million | CN¥139.74 Million | CN¥89.51 Million | ▼ -70.3% |
| 2013 | 2.15x | CN¥73.95 Million | CN¥34.32 Million | CN¥73.95 Million | ▼ -4.8% |
| 2012 | 2.26x | CN¥67.64 Million | CN¥29.88 Million | CN¥67.64 Million | ▼ -12.3% |
| 2009 | 2.58x | CN¥151.27 Million | CN¥58.61 Million | CN¥151.27 Million | ▲ +75.6% |
| 2008 | 1.47x | CN¥122.46 Million | CN¥83.31 Million | CN¥122.46 Million | ▲ +112.5% |
| 2007 | 0.69x | CN¥172.06 Million | CN¥248.71 Million | CN¥172.06 Million | ▼ -60.8% |
| 2006 | 1.77x | CN¥57.62 Million | CN¥32.62 Million | CN¥57.62 Million | ▼ -27.3% |
| 2005 | 2.43x | CN¥58.63 Million | CN¥24.12 Million | CN¥58.63 Million | ▲ +16.4% |
| 2004 | 2.09x | CN¥70.14 Million | CN¥33.59 Million | CN¥70.14 Million | ▼ -49.6% |
| 2003 | 4.14x | CN¥52.44 Million | CN¥12.65 Million | CN¥52.44 Million | — |